Heterotropic Activation of Cytochrome P450 3A4 by Perillyl Alcohol
<b>Background/Objectives</b>: Perillyl alcohol (POH), a monoterpene natural product derived from the essential oils of plants such as perilla (<i>Perilla frutescens</i>), is currently in phase I and II clinical trials as a chemotherapeutic agent. In this study, we investigated the effect of POH on cytochrome P450 (CYP) activity for evaluating POH-drug interaction potential. <b>Methods</b>: The investigation was conducted using pooled human liver microsomes (HLMs), recombinant CYP3A4 (rCYP3A4) enzymes, and human pluripotent stem cell-derived hepatic organoids (hHOs) employing liquid chromatography-tandem mass spectrometry. <b>Results</b>: POH inhibited the activities of CYP2A6 and CYP2B6 with K<sub>i</sub> of 6.35 and 3.78 μM, respectively, whereas it stimulated CYP3A4 activity in pooled HLMs incubated with midazolam (MDZ). In a direct CYP inhibition assay using HLMs, activities of CYP2C9, CYP2C19, and CYP2E1 were also inhibited by POH, with IC<sub>50</sub> values greater than 50 μM, but those of CYP1A2, CYP2C8, CYP2D6, and CYP3A4 (testosterone) were not significantly inhibited. In pooled HLMs, the V<sub>max</sub>/K<sub>m</sub> value of 1'-hydroxy MDZ, but not that of 4-hydroxy MDZ, was increased 2.7-fold by 100 μM POH compared with that in the absence of POH. Moreover, stimulation of MDZ 1'-hydroxylation by CYP3A4 was observed in hHOs and rCYP3A4 with cytochrome <i>b</i><sub>5</sub> but not rCYP3A4 without cytochrome <i>b</i><sub>5</sub>. Furthermore, activation of CYP3A4-mediated metabolism by POH was observed in HLMs incubated with fimasartan but not atorvastatin, buspirone, donepezil, nifedipine, or tadalafil, suggesting a substrate-dependent activation of CYP3A4 by POH. <b>Conclusions</b>: POH inhibits CYP2A6 and CYP2B6, but it activates CYP3A4. These findings underscore the need for further evaluation of the interactions of clinical drugs with POH.
Authors
- Jang Su Jeon (ORCID: https://orcid.org/0009-0009-6403-6006)
- Ji Hyeon Ryu (ORCID: https://orcid.org/0000-0003-0342-3108)
- Seongyea Jo
- Sang Kyum Kim (ORCID: https://orcid.org/0000-0001-5769-0792)
- Soo Min Lee (ORCID: https://orcid.org/0000-0003-1672-8779)
- Han‐Jin Park (ORCID: https://orcid.org/0000-0002-0113-4145)
- Soo Jin Oh (ORCID: https://orcid.org/0000-0001-5423-0440)
- Hyemin Kim (ORCID: https://orcid.org/0000-0002-3440-8456)
- Jieun Yu
Institutions
- Ulsan College (KR)
- Chungnam National University (KR)
- Asan Medical Center (KR)
- University of Ulsan (KR)
- Korea Institute of Toxicology (KR)
Publication Details
- Journal
- Pharmaceutics
- Published
- 2024-12-11
- DOI
- https://doi.org/10.3390/pharmaceutics16121581
- Citations
- 2
- Primary Topic
- Pharmacogenetics and Drug Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.93
Funders
- Korea Institute of Toxicology
- National Research Foundation of Korea